>>> US Early premarket gappers

Early premarket gappers
  • Gapping up:
    • HCC +4.3%, SOL +3.9%, SAVE +2.1%, SGML +1.6%, VMC +0.7%, MITK +0.7%, SONY +0.6%
  • Gapping down:
    • BIG -16.6%, VUZI -6.5%, IVVD -5.6%, APLD -3.7%, NVX -2.2%, AGR -2%, FULT -1.5%, GSK -1.3%, DOV -1%, FANG -0.8%, SSB -0.6%, SAP -0.6%

>>> Europe : Brokers Upgrades & Downgrades - 12th of February 2024 V3(++)

>>> Up
* Adyen Raised to Reduce at AlphaValue/Baader
* Carlsberg Raised to Neutral at UBS; PT 990 kroner (++)
* Cass Information Raised to Overweight at Piper Sandler; PT $51
* Finnair Raised to Accumulate at Inderes; PT 5 euro cents
* Hexatronic Raised to Buy at Danske Bank Markets; PT 45 kronor (++)
* Jupiter Raised to Neutral at BNPP Exane; PT 81 pence (+)
* Kemira Raised to Accumulate at Inderes; PT 19 euros
* Lloyds Raised to Market Perform at KBW; PT 50 pence
* Nexans PT Raised to 108 euros from 98 euros at Berenberg
* Proximar Seafood Raised to Buy at Pareto Securities; PT 4 kroner
* Renishaw Raised to Buy at UBS; PT 5,000 pence (++)
* Rockwool Raised to Buy at HSBC; PT 2,600 kroner
* Saab PT Raised to 800 kronor from 675 kronor at Carnegie (++)
* Siemens Energy Raised to Outperform at Grupo Santander (+)
* Siemens Energy Raised to Buy at BofA (++)
* Standard Chartered Raised to Market Perform at KBW; PT 790 pence
* Sweco Raised to Hold at ABG; PT 110 kronor
* Teva ADRs Raised to Overweight at Piper Sandler; PT $19
* Yara Raised to Buy at Nordea; PT 400 kroner

>>> Down
* Aker BP Cut to Hold at Berenberg; PT 270 kroner
* BP Cut to Reduce at AlphaValue/Baader
* EMS-Chemie Cut to Hold at Mirabaud Securities (+)
* Endomines Finland Cut to Sell at Inderes; PT 5.20 euros
* Hoegh Autoliners Cut to Neutral at Clarksons; PT 125 kroner
* HSBC Cut to Underperform at KBW; PT 700 pence
* Kemira Cut to Accumulate at OP Corporate Bank; PT 19 euros (++)
* Kongsberg Cut to Neutral at SpareBank; PT 630 kroner
* NatWest Cut to Underperform at KBW; PT 230 pence
* Odfjell Cut to Hold at Fearnley; PT 155 kroner (+)
* Orsted Cut to Neutral at Redburn; PT 400 kroner
* Phoenix Mecano Cut to Hold at Research Partners (+)
* Revenio Cut to Hold at Nordea
* Thule Cut to Hold at Carnegie (++)
* UnipolSai Cut to Reduce at Kepler Cheuvreux; PT 2.30 euros (++)
* Visiativ Cut to Neutral at Oddo BHF (+)

>>> Initiation
* Deliveroo Rated New Buy at Deutsche Bank; PT 180 pence
* Intertek Reinstated Neutral at BofA; PT 4,700 pence (+)
* Palmer Square Capital BDC Rated New Overweight at JPMorgan
* Pluxee France Rated New Overweight at JPMorgan; PT 33.50 euros
* Richemont Rated New Hold at Research Partners (+)
* SGS Reinstated Buy at BofA; PT 94 Swiss francs (+)
* Whitestone Group Rated New Buy at KBC Securities; PT 13.70 euros (++)

>>> Call
* Aker BP Downgraded to Hold at Berenberg as Outlook Weakens
* EU Tech Stocks' 2024 EPS Dragged by Lower Capex, High Inventory
* Hershey Gets Only Sell as Morgan Stanley Sees Risks to Outlook
* JPMorgan’s Matejka Says UK Stocks Trading at a Record Discount (+)
* Morgan Stanley’s Wilson Says Operational Efficiency Is in Focus
* Sweco Raised to Hold at ABG, Results Not as Bad as They Looked
* Thule Extends Gains on PT Hikes; Shakes Off Carnegie Downgrade (++)

>>> Europe : Brokers Upgrades & Downgrades - 12th of February 2024 V2(+)

>>> Up
* Adyen Raised to Reduce at AlphaValue/Baader
* Cass Information Raised to Overweight at Piper Sandler; PT $51
* Finnair Raised to Accumulate at Inderes; PT 5 euro cents
* Jupiter Raised to Neutral at BNPP Exane; PT 81 pence (+)
* Kemira Raised to Accumulate at Inderes; PT 19 euros
* Lloyds Raised to Market Perform at KBW; PT 50 pence
* Nexans PT Raised to 108 euros from 98 euros at Berenberg
* Proximar Seafood Raised to Buy at Pareto Securities; PT 4 kroner
* Rockwool Raised to Buy at HSBC; PT 2,600 kroner
* Siemens Energy Raised to Outperform at Grupo Santander (+)
* Standard Chartered Raised to Market Perform at KBW; PT 790 pence
* Sweco Raised to Hold at ABG; PT 110 kronor
* Teva ADRs Raised to Overweight at Piper Sandler; PT $19
* Yara Raised to Buy at Nordea; PT 400 kroner

>>> Down
* Aker BP Cut to Hold at Berenberg; PT 270 kroner
* BP Cut to Reduce at AlphaValue/Baader
* EMS-Chemie Cut to Hold at Mirabaud Securities (+)
* Endomines Finland Cut to Sell at Inderes; PT 5.20 euros
* Hoegh Autoliners Cut to Neutral at Clarksons; PT 125 kroner
* HSBC Cut to Underperform at KBW; PT 700 pence
* Kongsberg Cut to Neutral at SpareBank; PT 630 kroner
* NatWest Cut to Underperform at KBW; PT 230 pence
* Odfjell Cut to Hold at Fearnley; PT 155 kroner (+)
* Orsted Cut to Neutral at Redburn; PT 400 kroner
* Phoenix Mecano Cut to Hold at Research Partners (+)
* Revenio Cut to Hold at Nordea
* Visiativ Cut to Neutral at Oddo BHF (+)

>>> Initiation
* Deliveroo Rated New Buy at Deutsche Bank; PT 180 pence
* Intertek Reinstated Neutral at BofA; PT 4,700 pence (+)
* Palmer Square Capital BDC Rated New Overweight at JPMorgan
* Pluxee France Rated New Overweight at JPMorgan; PT 33.50 euros
* Richemont Rated New Hold at Research Partners (+)
* SGS Reinstated Buy at BofA; PT 94 Swiss francs (+)

>>> Call
* Aker BP Downgraded to Hold at Berenberg as Outlook Weakens
* EU Tech Stocks' 2024 EPS Dragged by Lower Capex, High Inventory
* Hershey Gets Only Sell as Morgan Stanley Sees Risks to Outlook
* JPMorgan’s Matejka Says UK Stocks Trading at a Record Discount (+)
* Morgan Stanley’s Wilson Says Operational Efficiency Is in Focus
* Sweco Raised to Hold at ABG, Results Not as Bad as They Looked

FT : Novo Holdings’ investment ambitions boosted by Ozempic and Wegovy income

Novo Holdings’ investment ambitions boosted by Ozempic and Wegovy income
Novo Nordisk’s controlling shareholder plans to allocate up to $7bn a year by 2030

Novo Holdings, the controlling shareholder of Danish drugmaker Novo Nordisk, plans to invest up to $7bn annually by 2030, as dividend payments from the maker of diabetes drug Ozempic and weight loss treatment Wegovy boost its coffers.

The life sciences investor manages the holdings of the Novo Nordisk Foundation, the world’s largest philanthropic body. This includes an investment portfolio valued at $24bn in 2022 consisting of life sciences and capital investments, in equities, bonds, real estate and infrastructure, as well as controlling stakes in companies Novo Nordisk and industrial enzymes maker Novozymes.

Kasim Kutay, Novo Holdings chief executive and a Novo Nordisk board member, told the Financial Times that rising income from its 28 per cent stake in Novo Nordisk and other investments would give his fund $5bn a year to invest in the next five years, rising to $7bn by 2030.

“We’ve got an ever growing investment portfolio that’s generating very attractive returns,” said Kutay. “That’s going to keep on growing, then we’ve got obviously the growth of . . . Ozempic and Wegovy and a lot of dividends . . . we have more money than ever to invest.”

The move marks an increase from $3bn in deals in 2023 and a step change in ambitions for Novo Holding’s investments portfolio. It booked a 6 per cent loss in 2022, a year the company described in its most recent annual report as “among the most challenging in recent memory, from both a geopolitical and economic perspective”.

The success of the Danish pharma group’s blockbuster weight-loss drugs helped it book record sales last year, pushing it to a $500bn market capitalisation.

Analysts expect the diabetes and weight loss category to reach $100bn in value by 2030, with demand for Ozempic and Wegovy forecast to remain high despite competition from rival Eli Lilly. “These are once in a generation drugs,” said Kutay.

The increased funds for Novo Holdings will be split equally between its capital investments and life sciences investments, with Kutay saying Novo Holdings’ investments in larger life sciences companies are “very scalable”. “What you’ll see us doing . . . is to start to do bigger deals and deploy more equity,” he said.

The bullish projection comes after Novo Holdings struck a $16.5bn deal on Monday to acquire Catalent, a pharmaceutical manufacturing company, before selling three Catalent sites for $11bn to Novo Nordisk, in which it holds the majority of voting rights.

Kutay said the deal was a “one-off” in scale that would enable Novo Nordisk to expand its manufacturing capacity for its blockbuster diabetes and weight loss drugs by 2026, while also providing Novo Holdings with a pharmaceutical services asset, an area in which it has other investments.

It was “too early to tell” if Novo Holdings would sell off parts of Catalent, but he said this was “not part of the core thesis”.

The Catalent sites specialise in “fill-finish” operations, the final part of manufacturing syringe-based products like Ozempic. The company is also a partner for several pharmaceutical companies.

Eli Lilly chief executive David Ricks described the acquisition as “unusual” on Tuesday and called for competition authorities to look into the deal. AstraZeneca chief executive Pascal Soriot said on Thursday that the move showed the need for pharmaceutical companies to have “independent” supply chains.

Kutay declined to comment on Ricks’ concerns but said Novo Nordisk had committed to honouring existing contracts with manufacturers. He said: “Ultimately, at some point in the future, those sites will be either fully or close to fully dedicated to supplying [Novo Nordisk].”

FT : Total boss warns governments risk mis-selling energy transition

Total boss warns governments risk mis-selling energy transition
States must acknowledge shift to less-polluting system will lead to higher energy costs

The long-serving chief executive of France’s TotalEnergies has warned that governments are mis-selling the energy transition if they fail to acknowledge the shift to a less-polluting system will lead to higher energy costs.

“We think that fundamentally this energy transition will mean a higher price of energy,” Patrick Pouyanné said in a wide-ranging interview, in which he defended his group’s two-pronged strategy to invest in renewable power, while still pursuing new oil and gas projects decried by climate activists, including in untapped countries such as Namibia.

Policymakers and campaigners were naive, he argued, to think it will be possible to shrink oil and gas production before sufficient renewable energy is available to take its place, given continued growth in global energy demand.

“The pace of transition will not be the same everywhere,” he said. “We cannot ask African countries just to avoid to develop the resources because we have developed their resources for our own comfort for 20 years.”

Since rising to the top of TotalEnergies in 2014, Pouyanné’s strategy and messaging has been among the most consistent in the industry.

While European rivals BP and Shell have vacillated over how to invest in the energy transition and how quickly to withdraw from oil and gas, Pouyanné has remained steadfast in his commitment to fossil fuel production, while still spending more than competitors on renewable energy projects in more recent years.

The result is a comparatively simple strategy based on three pillars — oil, gas and integrated power — to which investors have generally responded positively. Returns to shareholders at TotalEnergies have beaten rivals since Pouyanné took over almost a decade ago.

“I need to continue to be strong in oil and gas . . . people are first buying your shares because of that,” he said.

Out of $16.8bn in capital spending in 2023, approximately two-thirds were spent on oil and gas and one-third on the group’s “low-carbon” integrated power business. That level of investment is now plateauing from one year to the next rather increasing, climate activists point out.

However, Pouyanné was also adamant that he is not investing in wind and solar projects just to reduce the company’s emissions. Unlike some in the oil and gas industry, he sees power as an increasingly profitable opportunity, particularly as he expects the energy transition to result in permanently elevated electricity prices.


“I know that there is a theory which says renewables are cheaper, so it will be a lower price,” he said. “We don’t think so because a system where you [have] more renewable intermittency is less efficient . . . so we think it’s an interesting field to invest in.”

He expects the integrated power division to become cash flow positive in 2028, when it will generate about $4bn, hopefully with a return on average capital employed of 12 per cent. That is equivalent to returns in the company’s oil business when crude is trading at $60 a barrel, the company says.

The integrated power business will continue to grow organically or through targeted project level deals, rather than through a big acquisition, Pouyanné said, adding that he thought most renewables companies were still overvalued, despite a sell-off in the past 12 months.

“I don’t need Ørsted. What do they bring to me?” he said, referring to the world’s largest offshore wind developer whose share price has fallen more than 70 per cent since peaking in 2021 at the height of investor frenzy over environmentally friendly stocks. “This question could have been asked three years ago, but we have developed our own portfolio.”

The integrated power strategy has not been without setbacks. Last year it suspended a $4bn green hydrogen investment with India’s Adani after a short seller report accused the conglomerate of accounting fraud and stock market manipulation, which it strongly denied.

Pouyanné said he now considered the Adani “case over” and was doubling down on renewable energy ventures with the group, although the hydrogen project remained on the backburner as demand in this market was still tentative.

TotalEnergies’ traditional fossil fuel business will be vital to funding the growth of its electricity assets and maintaining returns in the meantime, Pouyanné argued.

“If you begin to say ‘because I’m investing in the transition, I need to lower my returns’ this will not work,” he said. TotalEnergies returned $16.5bn to shareholders last year in dividends and share buybacks, representing 46 per cent of cash flow from operations.

The company plans to increase oil and gas output by a combined 2-3 per cent a year until 2030, a strategy that has alienated some investors but won over others. The number of US-based shareholders in the company has increased from less than 40 per cent to 47 per cent over the past two years, Pouyanné said.

BP in contrast has committed to cut oil and gas production by 25 per cent by 2030, compared with 2019 levels, although that is down from a previous target of 40 per cent after it pared back the ambition last year.

Much of TotalEnergies’ additional oil and gas production will come from new projects in Uganda, Mozambique, Iraq, Papua and Brazil. These have made the group a lightning rod for criticism from climate campaigners and a target of political criticism at home.

Pouyanné and the group face an inquiry this year launched by green politicians in the French Senate over its record on environmental goals.

But while many European and North American producers have pulled back from frontier markets, Pouyanné views a capacity to keep operating in such places as an advantage. The company, which was founded in Iraq in 1924, has a long history in the Middle East and merged with Africa-focused Elf in 2000.

“My friends and my main competitors do not like to take the risk, so we take it,” Pouyanné said. “It’s balancing risk and reward. The condition for us to go into these countries . . . is to have better returns.”

In Namibia, for example, which does not have an existing oil and gas industry, TotalEnergies has found promising hydrocarbons deposits offshore.

“We are perfectly aware that any new oil and gas development could become an issue but the question for me is more what does Namibia want?” Pouyanné asked. “I don’t think it’s western NGOs who need to decide the future of Namibia.”

Pouyanné is an unabashed defender of what he presents as a pragmatic worldview, arguing that oil demand may peak before the end of this decade but will decline slowly enough after that new production will be required. 

“There is a sort of divide today between the global south and the north on this perspective, which we have observed in Dubai as well, in the way the debate happened,” Pouyanné said, referring to the COP 28 climate talks December.

In Iraq, where TotalEnergies is involved in a $27bn series of gas, oil and solar projects, the government’s principal preoccupation is developing gas for domestic power generation and increased oil production will be used to pay for it, he said.

“If we don’t engage with the global south where the emissions will come from — China, from India, from Brazil, from South Africa — if we don’t engage with them by bringing them energy, there is no way to find a solution to the climate.”

In Europe, having significantly reduced dependence on Russian gas — a chunk of which is still provided by Total’s stake in the Yamal liquefied natural gas project led by Russia’s Novatek — leaders needed to keep diversifying sources of supply, Pouyanné warned.

In particular, they should seek to protect long-term imports of LNG from the US, which is now its biggest supplier, he argued.

Last month President Joe Biden imposed a temporary pause on new licenses to export LNG to countries without a free trade agreement with Washington, which includes the EU.

“The US says that they can help Europe with their security of supply,” he said. “Let’s negotiate that agreement.”

FT : Private equity chiefs enjoy $40bn gain in share value as assets surge

Private equity chiefs enjoy $40bn gain in share value as assets surge
High interest rates have provided good news, with earnings boosted by growth of credit operations

The founders and top executives of the largest private equity groups in the US have seen the value of their shares rise by over $40bn since the beginning of 2023 as new assets have poured into their firms.

Shares in Blackstone, KKR, Apollo Global, Ares Management and TPG have neared or eclipsed record highs due to better-than-feared financial results. Those earnings were buoyed by growth in the firms’ overall assets, particularly credit and insurance-based investment operations, which benefited from fast-rising interest rates.

The stock gains have come at a time of unease across Wall Street and underscored the groups’ diversification away from traditional corporate buyouts, which slowed dramatically last year.

Large investment banks have cut staff and slashed bonuses amid a slowdown in dealmaking caused by the rate increases. While private equity groups have struggled to sell investments and return profits to investors who are increasingly short on cash, higher yields have bolstered their less-heralded lending businesses, where assets and returns surged.

In 2023, $148bn of new investor money flowed into Blackstone, pushing its assets above $1tn, with the majority last year coming from its credit and insurance operations. Its private credit investments gained 16.4 per cent last year, results that helped to blunt earnings declines in its private equity unit.

Apollo Global raised even more, with $157bn of gross inflows in 2023. Nearly half came from its Athene insurance unit.

“The asset gathering over the past year has been extraordinary,” said Macrae Sykes, a portfolio manager for the Gabelli Equity Trust, which owns shares in both groups.

The Financial Times calculated gains since the beginning of 2023 on the shares of about 30 founders and executives named in proxy filings, including those of Carlyle Group. Blackstone’s Stephen Schwarzman saw his holdings increase the most, gaining over $12bn in value.

Blackstone has generated an 80 per cent total return when including dividends since 2023 and is now the world’s largest asset manager by market value. Its $155bn market capitalisation is also larger than Morgan Stanley or Goldman Sachs.

On an earnings call last month, Schwarzman said the group’s increasingly diversified business had insulated it from recent market turmoil. “We’ve designed the firm to provide resiliency in times of stress and capture the upside as markets recover,” he told analysts.

“These companies are proving that there are multiple avenues of growth for them by product, region and distribution channel,” said William Katz, an analyst at TD Cowen.

Collectively, the private equity groups generated $15.5bn in fee and spread-based earnings in 2023, an 11 per cent increase from the prior year.

Private equity groups stepped into fractured loan markets last year after the collapse of three large US regional lenders. Apollo Global originated nearly $100bn in debt in 2023, including large loans to German property group Vonovia and to Air France-KLM. Its lending was fuelled by its purchase of the securitised products unit of Credit Suisse a year ago, now called Atlas SP, and over a dozen other lending platforms it has built or acquired.

Blackstone struck lending partnerships with large regional US banks to help them originate debts, president Jonathan Gray told the Financial Times last year.

Other groups completed large acquisitions to bolster their credit investment capabilities. In November, TPG acquired credit investment group Angelo Gordon for $2.7bn, while KKR earlier this year took full ownership of insurer Global Atlantic, purchasing a remaining 37 per cent stake at a valuation of over $7bn.

Marc Rowan, chief executive of Apollo Global, has attributed the industry’s growth to a changing financial system in which an era of low rates and higher regulations pushed activity away from public markets and the banking system.

“In 2008, we had $44bn of assets under management . . . We’ve grown 14-times. That’s faster than Apple’s revenue [growth],” Rowan said last week, referring to Apollo’s $652bn in overall assets.

“I’d like to think that was all as a result of management acumen . . . but we are the beneficiary of macro industry factors that drove not just us, but our entire industry.”